Exicure Valuation
Is 2H0A undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of 2H0A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 2H0A für die Bewertungsanalyse.
Deutlich unter dem Marktwert: Unzureichende Daten zur Berechnung des beizulegenden Zeitwerts von 2H0A für die Bewertungsanalyse.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 2H0A?
Other financial metrics that can be useful for relative valuation.
| What is 2H0A's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$4.84m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.4x |
| Enterprise Value/EBITDA | 2.2x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 2H0A's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 17.7x | ||
BIO3 Biotest | 9.1x | -53.2% | €1.4b |
MPH Medicure | 10.2x | n/a | CA$11.1m |
GEN Genomed Spólka Akcyjna | 39.2x | n/a | zł38.8m |
NSB NeuroScientific Biopharmaceuticals | 12.3x | n/a | AU$9.4m |
2H0A Exicure | 1.6x | n/a | €4.8m |
Price-To-Earnings gegen Gleichaltrige: 2H0A ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (1.7x) mit dem Durchschnitt der anderen Unternehmen (22.9x) vergleicht.
Price to Earnings Ratio vs Industry
How does 2H0A's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Earnings gegen Industrie: 2H0A ist aufgrund seines Price-To-Earnings Verhältnisses (1.7x) im Vergleich zum European Biotechs Branchendurchschnitt (35.4x) ein guter Wert.
Price to Earnings Ratio vs Fair Ratio
What is 2H0A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 1.6x |
| Fair PE Ratio | n/a |
PM vs. Fair Ratio: Unzureichende Daten zur Berechnung der Price-To-Earnings Fair Ratio von 2H0A für die Bewertungsanalyse.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analysten-Prognose: Unzureichende Daten für eine Preisprognose.